These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9082531)

  • 1. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A close look at fenfluramine and dexfenfluramine.
    Vivero LE; Anderson PO; Clark RF
    J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical observations on the treatment of obese patients with dexfenfluramine].
    Cairella M; Pisculli M; Petraroli AR; Riganelli S; Saracino A; Siani V
    Clin Ter; 1990 Jun; 133(5):289-97. PubMed ID: 2143712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with fenfluramine in obese subjects.
    Sensi S; Della Loggia F; Del Ponte A; Guagnano MT
    Int J Clin Pharmacol Res; 1985; 5(4):247-53. PubMed ID: 4055167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
    Galletly C; Clark A; Tomlinson L
    Int J Eat Disord; 1996 Mar; 19(2):209-12. PubMed ID: 8932560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
    Sabuncu T; Ucar E; Birden F; Yasar O
    Diabetes Nutr Metab; 2004 Apr; 17(2):103-7. PubMed ID: 15244102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and acceptability of dexfenfluramine in women consulting in gynecology. 336 overweight patients treated for 3 months].
    Elia D; Auclair J; Rey C
    Rev Fr Gynecol Obstet; 1992 Jun; 87(6):361-9. PubMed ID: 1631479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N; Ryan DH; Renz CL; Hewkin AC
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
    Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.